ConductScience.org, home

Trial · NCT03426124

Outcomes12

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYChange in RV/LV Ratio on Echocardiogram (Matched Pairs as Available)Baseline to post-procedure (end of procedure through hospital discharge up to 14 days)Subjects with matched pairs (pre-procedure echocardiogram and post-procedure echocardiogram through discharge from index hospitalization) have been reported.Percent changeMEAN
PRIMARYFrequency and Safety Outcomes of Subjects Requiring Interventions of Adjunctive Therapies Post-procedure During Hospitalization.Post-procedure hospitalization through hospital discharge up to 14 daysParticipantsCOUNT_OF_PARTICIPANTS
PRIMARYNumber of Patients Who Underwent Interventional Therapies Prior to the APT Procedure and Experienced a Non- or Partial- Response.From date of enrollment up to or until the placement of the Ekos device, on average 48 hours.ParticipantsCOUNT_OF_PARTICIPANTS
PRIMARYNumber of Patients Experiencing a SAEs Related to EKOS Device and/or Procedure During First 12 Months Post-APT Procedure.From time of APT procedure through 12 months post-procedure.ParticipantsCOUNT_OF_PARTICIPANTS
PRIMARYAll-cause Mortality During First 12 Months Post-procedure.Start of procedure through 12 months post-procedure.Retrospective data to be updated.ParticipantsCOUNT_OF_PARTICIPANTS
PRIMARYHealthcare UtilizationMeasured as time from ICU admission to ICU discharge in hours (from date of enrollment through 12 months post-procedure).HoursMEDIAN
PRIMARYChange in Quality of Life (QOL) as Measured by the Pulmonary Embolism Quality of Life (PEmb-QOL) at the 3 Month and 12 Month Post-hospitalization Follow-up VisitsMeasured as percent change in time from baseline assessment at discharge to 3 month and 12 month follow up.QOL date were not collected in the retrospective cohort. These questionnaires were only collected prospectively.percentage changeMEAN
PRIMARYChange in Quality of Life (QOL) as Measured by the EQ-5D-5L VAS, Utility and Misery Scores at the 3-month and 12-month Post-hospitalization Follow-up Visits.Reported results include change from baseline to 3 months and 12 months post-procedure for prospective patients.Data for the retrospective cohort were not captured as Quality of Life questionnaires were not Standard of Care at most institutions.units on a scaleMEAN
PRIMARYNumber of Patients Needing an IVC Filter PlacementFrom date of procedure through 12 monthsParticipantsCOUNT_OF_PARTICIPANTS
PRIMARYNumber of Patients Experiencing Adverse Events Classified as Major Bleeding Events During First 12 Months Post-Procedure by Frequency and SeverityFrom post-procedure through 12-months post-procedureParticipantsCOUNT_OF_PARTICIPANTS
PRIMARYNumber of Patients Experiencing VTE (Venus Thromboembolytic Events) During First 12 Months Post-Procedure by Frequency and Severity.From post-procedure through 12-months post-procedureParticipantsCOUNT_OF_PARTICIPANTS
PRIMARYDiagnosis of Pulmonary Hypertension DiagnosisAnalyzed 12 months post-procedureParticipantsCOUNT_OF_PARTICIPANTS

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03426124/outcomes